|
|
|
题名
|
作者
|
年代
|
出处
|
被引量
|
| 1 | The ageing gut: diminished symptom response to a standardized nutrient stimulus显示文摘 | M.Gururatsakul R. H.Holloway B.Adam T.Liebregts N. J.Talley G. J.Holtmann | 2010 | Neurogastroenterology & Motility2010，，3： | 1 |
| 2 | Overlap of gastro‐oesophageal reflux disease and irritable bowel syndrome: prevalence and risk factors in the general population显示文摘 | H.‐K.JUNG S.HALDER M.MCNALLY G. R.LOCKE III C. D.SCHLECK A. R.ZINSMEISTER N. J.TALLEY | 2007 | Alimentary Pharmacology & Therapeutics2007，，3： | 1 |
| 3 | Review article: current treatment options and management of functional dyspepsia显示文摘 | N. J.Talley E. P.Bouras H. B.El‐Serag C. W.Howden C.Prather | 2012 | Aliment Pharmacol Ther2012，，1： | 1 |
| 4 | Vacuum油田的动态储层特征描述显示文摘时间延迟多分量地震测量可以进行动态储层特征描述以及生成动态储层模型。实际上,在降低风险和环境影响时,它还有助于经济有效的组织和技术决策,从而延长储层寿命和提高采收率。 本文简要介绍了由科罗拉多矿业学院储层特征描述项目(RCP)组开发的4D。 | Daniel J.Talley 袁联生 | 1999 | 石油物探译丛1999，，2： | 1 |
| 5 | Development and validation of the Diabetes Bowel Symptom Questionnaire显示文摘 | C.Quan N. J.Talley S.Cross M.Jones J.Hammer N.Giles M.Horowitz | 2003 | Alimentary Pharmacology & Therapeutics2003，，9： | 1 |
| 6 | Functional gastrointestinal disorders as a public health problem显示文摘 | N. J.Talley | 2008 | Neurogastroenterology & Motility2008，，： | 1 |
| 7 | Characterizing abdominal pain in IBS: guidance for study inclusion criteria, outcome measurement and clinical practice显示文摘 | B. M. R.Spiegel R.Bolus L. A.Harris S.Lucak W. D.Chey G.Sayuk E.Esrailian A.Lembo H.Karsan K.Tillisch J.Talley L.Chang | 2010 | Alimentary Pharmacology & Therapeutics2010，，9： | 1 |
| 8 | Is there a benefit from intensified medical and psychological interventions in patients with functional dyspepsia not responding to conventional therapy?显示文摘 | S.HAAG W.SENF S.TAGAY M.LANGKAFEL U.BRAUN‐LANG A.PIETSCH G.HEUFT N. J.TALLEY G.HOLTMANN | 2007 | Alimentary Pharmacology & Therapeutics2007，，8： | 1 |
| 9 | Esomeprazole 20?mg maintains symptom control in endoscopy‐negative gastro‐oesophageal reflux disease: a controlled trial of ‘on‐demand’ therapy for 6?months显示文摘 | N. J.Talley K.Lauritsen H.Tunturi‐Hihnala T.Lind B.Moum C.Bang T.Schulz T. M.Omland M.Delle O.Junghard | 2008 | Alimentary Pharmacology & Therapeutics2008，，3： | 1 |
| 10 | Irritable bowel syndrome aggregates strongly in families: a family‐based case‐control study显示文摘 | Y. A.Saito J. M.Zimmerman W.S. Harmsen M.De Andrade G. R.Locke Iii G. M.Petersen N. J.Talley | 2008 | Neurogastroenterology & Motility2008，，7： | 1 |
| 11 | Epidemiology of the functional gastrointestinal disorders diagnosed according to Rome II criteria: an Australian population‐based study显示文摘 | P. M.Boyce N. J.Talley C.Burke N. A.Koloski | 2005 | Internal Medicine Journal2005，，1： | 1 |
| 12 | Biliary events and an increased risk of new onset irritable bowel syndrome: a population‐based cohort study显示文摘 | M. A.MCNALLY G. R.LOCKE A. R.ZINSMEISTER C. D.SCHLECK J.PETERSON N. J.TALLEY | 2008 | Alimentary Pharmacology & Therapeutics2008，，3： | 1 |
| 13 | The prevalence and clinical course of functional dyspepsia显示文摘 | H. B.El‐Serag N. J.Talley | 2004 | Alimentary Pharmacology & Therapeutics2004，，6： | 1 |
| 14 | Development and validation of a patient‐assessed gastroparesis symptom severity measure: the Gastroparesis Cardinal Symptom Index显示文摘 | D. A.Revicki A. M.Rentz D.Dubois P.Kahrilas V.Stanghellini N. J.Talley J.Tack | 2003 | Alimentary Pharmacology & Therapeutics2003，，1： | 1 |
| 15 | Is it possible to predict treatment response to a proton pump inhibitor in functional dyspepsia?显示文摘 | E.Bolling‐Sternevald K.Lauritsen N. J.Talley O.Junghard H.Glise | 2003 | Alimentary Pharmacology & Therapeutics2003，，1： | 1 |
| 16 | Helicobacter pylori serology in a birth cohort of New Zealanders from age 11 to 26显示文摘AIM: To determine seroprevalence of Helicobacter pylori (Hpylori) in the Dunedin Multidisciplinary Health and Development Study (DMHDS) at age 26 in order to investigate seroconversion and seroreversion from age 11 to 26 and the association of seropositivity with risk factors for Hpylori infection.METHODS: Participants in the DMHDS at age 26 and retrospectively at age 21 were tested for H pylori antibodies using two commercially available ELISA kits. Gender, socioeconomic status (SES), smoking, educational attainment and employment at age 26 were tested for association with H pylori seropositivity.RESULTS: At ages 21 and 26, seroprevalence of Hpylori using one or other kit was 4.2% (n = 795) and 6.3% (n = 871) respectively. Seroreversion rate was lower than seroconversion rate (0.11% vs0.53% per person-year) in contrast to the period from age 11 to 21 when seroreversion rate exceeded seroconversion rate (0.35% vs 0.11% perperson-year). Serology in those tested at ages 11, 21,and 26 remained unchanged in 93.6% of the sample.Seroprevalence at age 26 was lower among those with a secondary school qualification (P = 0.042) but was not associated with gender, SES, smoking or employment status.CONCLUSION: Hpylodseroprevalence in a New Zealand birth cohort remains low between ages 11 and 26. H pylori infection remains stable from childhood to adulthood although seroreversion seems to be more common in the adolescent years than in young adults. | J.Paul Fawcett Gill O.Barbezat Richie Poulton Barry J.Milne Harry H.X.Xia Nicholas J.Talley | 2005 | World Journal of Gastroenterology2005，11，21： | 0 |
您所在的机构暂未开通此部分的功能，请联系管理员